Tricyclics: possible treatment for posttraumatic stress disorder.
The response to tricyclic antidepressants (TCAs) was examined in 17 combat veterans with DSM-III defined posttraumatic stress disorder (PTSD) by means of concurrent and retrospective chart review. Severity and improvement were determined by means of Clinical Global Impressions (CGI) ratings by two independent but nonblind raters who demonstrated satisfactory reliability. Prior to treatment, 82% were rated as markedly or severely ill and 18% as moderately ill. Following treatment, 82% were rated as much improved and 18% as minimally improved. The results support further investigation of TCAs for the treatment of PTSD.
D000328:Adult; D000639:Amitriptyline / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003130:Combat Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003891:Desipramine / Q000627:therapeutic use; D004316:Doxepin / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008370:Manuals as Topic; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy*
D000929:Antidepressive Agents, Tricyclic; D004316:Doxepin; D000639:Amitriptyline; D007099:Imipramine; D003891:Desipramine